Gammapatía monoclonal que evoluciona a amiloidosis sistémica con compromiso cardíaco. Reporte de caso

Germán Valenzuela-Rodríguez; Ofelia Araoz Tarco; Iván Fernández Vertiz

doi:10.47487/apcyccv.v6i2.477

Authors

Germán Valenzuela-Rodríguez Clínica Delgado, Lima, Perú; Unidad de Revisiones Sistemáticas y Metaanálisis (URSIGET), Vicerrec- torado de Investigación, Universi- dad San Ignacio de Loyola, Lima, Perú. https://orcid.org/0000-0002-8595-9549
Ofelia Araoz Tarco Clínica Delgado, Lima, Perú; Instituto Nacional Cardiovascular INCOR, Lima, Perú. https://orcid.org/0000-0001-7755-8174
Iván Fernández Vertiz Clínica Delgado, Lima, Perú; Hospital Nacional Edgardo Reba- gliati Martins, Lima, Perú. https://orcid.org/0000-0001-7472-8692

DOI:

https://doi.org/10.47487/apcyccv.v6i2.477

Keywords:

Light Chain Amyloidosis, Cardiac, Monoclonal Gammopathy of Undetermined Significance

Abstract

We report a case of systemic light chain amyloidosis with cardiac involvement, preceded by a monoclonal IgG lambda gammopathy. The clinical diagnosis was based on signs of heart failure, elevated biomarkers, and imaging findings. The diagnosis was confirmed by elevated light chains in the blood and urine, and the presence of amyloid deposits in the periumbilical fat biopsy and in different segments of the digestive tract. Treatment with daratumumab plus bortezomib plus dexamethasone was initiated, and autologous hematopoietic stem cell therapy was administered 22 months after diagnosis, with a favorable clinical outcome.

Downloads

Download data is not yet available.

References

Sekiguchi Y, Wakabayashi M, Iizuka H, Takizawa H, Sugimoto K, Sakajiri S, et al. Significant role of magnetic resonance imaging for the diagnosis and evaluation of cardiac amyloidosis in primary light chain amyloidosis. J Clin Exp Hematop. 2020;60(3):97-102. doi: 10.3960/jslrt.19040.

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995. doi: 10.1200/JCO.2011.38.5724.

Cuddy SAM, Falk RH. Amyloidosis as a Systemic Disease in Context. Can J Cardiol. 2020;36:396-407. doi: 10.1016/j.cjca.2019.12.033.

Gonsalves W, Rajkumar SV. Monoclonal Gammopathy of Undetermined Significance. Ann Intern Med. 2022;175(12):1169-1180. doi: 10.7326/AITC202212200.

Kyle RA, Larson DR, Therneau TM, Dispinzieri A, Kumar S, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2018;378(3):241-249. doi: 10.1056/NEJMoa1709974.

Llerena-Velastegui J, Zumbana-Podaneva K. Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review. Cardiol Res. 2024;15(4):211-222. doi: 10.14740/cr1664.

Bukhari S. Cardiac amyloidosis: state-of-the-art-review. J Geriatr Cardiol. 2023;20(5):361-375. doi:10.26599/1671-5411.2023.05.006.

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554-1568. doi: 10.1093/eurheartj/ehab072.

Stern LK, Kittleson MM. Updates in Cardiac Amyloidosis Diagnosis and Treatment. Curr Oncol Rep. 2021 Mar 16;23(4):47. doi: 10.1007/s11912-021-01028-8.

Rubin K, Maurer MS. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med. 2020;71:203-219. doi: 10.1146/annurev-med-052918-020140.

Bukhari S, Bashir Z. Diagnostic Modalities in the Detection of Cardiac Amyloidosis. J Clin Med. 2024;13(14):4075. doi: 10.3390/jcm13144075.

Dorbala S, Cuddy S, Falk RH. How to Image Cardiac Amyloidosis: A Practical Approach. JACC Cardiovasc Imaging. 2020;13(6):1368-1383. doi: 10.1016/j.jcmg.2019.07.015.

Kumar S, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, et al. Systemic Ligh Chain Amyloidosis, Version 2.2023. J Natl Compr Canc Netw. 2023;21(1):67-81. doi: 10.6004/jnccn.2023.0001.

Salinas-Arce J, Alca-Clares R, Gonzales-Luna AC, Cabrera-Saldaña M, Mendoza-Novoa P, Solórzano-Altamirano P, et al. Las arritmias en la amiloidosis cardíaca. Arch Peru Cardiol Cir Cardiovasc. 2022;3(2):82-

doi:10.47487/apcyccv.v3i2.217.

Younis M, Ogbu I, Kalra DK. Optimizing drug therapies in cardiac amyloidosis. Pharmacol Ther. 2025;265:108758. doi: 10.1016/j.pharmthera.2024.108758.

Kawano Y, Hata H, Takashio S, Tsujita K, Ueda M, Matsuoka M. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma. Br J Haematol. 2022;198:e38-e41. doi: 10.1111/bjh.18234.

Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, et al. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. J Clin Oncol. 2023;41(7):1393-1403. doi: 10.1200/JCO.22.00643.